1-[(6-氯-3-吡啶基)磺酰基]-4-甲基-哌嗪 | 64614-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-[(6-氯-3-吡啶基)磺酰基]-4-甲基-哌嗪
• 英文名称: 1-(6-chloro-pyridine-3-sulfonyl)-4-methyl-piperazine
• 英文别名: 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine；1-(6-chloropyridin-3-yl)sulfonyl-4-methylpiperazine
• CAS: 64614-53-5
• 化学式: C₁₀H₁₄ClN₃O₂S
• mdl: MFCD03988227
• 分子量: 275.759
• InChiKey: KJNDIWBXKRQJHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-[(6-氯-3-吡啶基)磺酰基]-4-甲基-哌嗪 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 生成 1-[(6-Hydrazinylpyridin-3-yl)sulfonyl]-4-methylpiperazine
  参考文献：
  名称：

  Inhibition of cancer cell invasion by new ((3,4-dihydroxy benzylidene)hydrazinyl)pyridine-3-sulfonamide analogs

  摘要：

  Rab GTPases regulate various types of intracellular membrane trafficking in all eukaryotes. Since Rab27a and its multiple effectors are involved in exocytosis of lysosome-related organelles and play a major role in malignancy, compounds targeting Rab27a could be likely used to inhibit invasive growth and tumor metastasis. Thus, we designed and synthesized several compounds based on the previously reported Rab27a-targeting synthetic compounds identified by virtual screening, and investigated their anti-metastatic effects in MDA-MB231 and A375 cells. Among the synthesized compounds, (E)-N-(3-chlorophenyl)-6-(2-(3,4-dihydroxy benzylidene)hydrazinyl)pyridine-3-sulfonamide (3d) and (E)-N-benzyl-6-(2-(3,4-dihydroxy benzylidene)hydrazinyl)-N-methylpyridine-3-sulfonamide (3f) significantly inhibited the invasiveness of both tumor cell lines. Compounds 3d and 3f also decreased the levels of signature extracellular matrix marker proteins (fibronectin, collagen, and a-smooth muscle actin) and representative mesenchymal cell markers (N-cadherin and vimentin). Taken together, our results suggest that novel sulfonamide analogs have anti-metastatic activity in breast and melanoma cancer cell lines and may be used as therapeutic agents to treat malignant cancer. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.12.093
• 作为产物：
  描述：

  N-甲基哌嗪 、 2-氯吡啶-5-磺酰氯 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 氯仿 、 水 、 乙酸乙酯 为溶剂， 生成 1-[(6-氯-3-吡啶基)磺酰基]-4-甲基-哌嗪
  参考文献：
  名称：

  Inhibition of cancer cell invasion by new ((3,4-dihydroxy benzylidene)hydrazinyl)pyridine-3-sulfonamide analogs

  摘要：

  Rab GTPases regulate various types of intracellular membrane trafficking in all eukaryotes. Since Rab27a and its multiple effectors are involved in exocytosis of lysosome-related organelles and play a major role in malignancy, compounds targeting Rab27a could be likely used to inhibit invasive growth and tumor metastasis. Thus, we designed and synthesized several compounds based on the previously reported Rab27a-targeting synthetic compounds identified by virtual screening, and investigated their anti-metastatic effects in MDA-MB231 and A375 cells. Among the synthesized compounds, (E)-N-(3-chlorophenyl)-6-(2-(3,4-dihydroxy benzylidene)hydrazinyl)pyridine-3-sulfonamide (3d) and (E)-N-benzyl-6-(2-(3,4-dihydroxy benzylidene)hydrazinyl)-N-methylpyridine-3-sulfonamide (3f) significantly inhibited the invasiveness of both tumor cell lines. Compounds 3d and 3f also decreased the levels of signature extracellular matrix marker proteins (fibronectin, collagen, and a-smooth muscle actin) and representative mesenchymal cell markers (N-cadherin and vimentin). Taken together, our results suggest that novel sulfonamide analogs have anti-metastatic activity in breast and melanoma cancer cell lines and may be used as therapeutic agents to treat malignant cancer. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.12.093

文献信息

• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2003082853A1

  公开（公告）日：2003-10-09

  The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明提供了式Ia和Ib的新化合物，以及它们的制备方法和在其中使用的新中间体，含有这些治疗活性化合物的药物配方，以及这些活性化合合物在治疗中的使用。
• Compounds
  申请人：Berg Stefan

  公开号：US20050153987A1

  公开（公告）日：2005-07-14

  The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明提供了公式Ia和Ib的新化合物：以及用于它们的制备的新中间体，包含所述治疗活性化合物的制药配方以及在治疗中使用所述活性化合物的用途。
• 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3)
  申请人：Berg Stefan

  公开号：US20080275041A1

  公开（公告）日：2008-11-06

  Compounds of formula Ia or Ib wherein P; R 1 ; R 2 ; m; and n are as defined in the application, salts thereof, processed for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.

  本发明涉及式Ia或Ib化合物，其中P; R1; R2; m;和n如本申请中所定义，其盐，用于其制备的加工，其中使用的新中间体，含有所述化合物的制药配方以及所述化合物在治疗中的使用。
• 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3
  申请人：AstraZeneca AB

  公开号：US07399780B2

  公开（公告）日：2008-07-15

  The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明提供了公式Ia和Ib的新化合物：以及它们的制备方法和其中使用的新中间体，含有该治疗活性化合物的药物制剂以及该活性化合物在治疗中的使用。
• New Compounds
  申请人：Berg Stefan

  公开号：US20090149460A1

  公开（公告）日：2009-06-11

  The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明提供了公式Ia和Ib的新化合物，以及用于其制备的新中间体，含有该治疗活性化合物的制药配方以及在治疗中使用该活性化合物的用途。